Attached files
| file | filename |
|---|---|
| EX-99.1 - LETTER TO STOCKHOLDERS DATED SEPTEMBER 2, 2016 - MABVAX THERAPEUTICS HOLDINGS, INC. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 2, 2016
MABVAX THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
000-31265
|
93-0987903
|
||
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
11535 Sorrento Valley Rd., Suite 400
San Diego, CA 92121
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (858) 259-9405
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01 Regulation FD Disclosure.
The disclosure under item 8.01 is incorporated herein by reference.
Item 8.01 Other Events.
On September 2, 2016 MabVax Therapeutics Holdings Inc. mailed a letter to stockholders disclosing clinical and corporate development milestones. A copy of the letter to stockholders is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The exhibit listed in the following Exhibit Index is furnished with this Current Report on Form 8-K.
|
Exhibit No.
|
Description
|
||
| 99.1 |
Letter to Stockholders dated September 2, 2016
|
||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MABVAX THERAPEUTICS HOLDINGS, INC.
|
|||||||
|
Dated: September 7, 2016
|
/s/ J. David Hansen | ||||||
|
J David Hansen
|
|||||||
|
Chairman and Chief Executive Officer
|
|||||||